Description: OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Home Page: www.oncocyte.com
0KCC Technical Analysis
15 Cushing
Irvine,
CA
92618
United States
Phone:
949 409 7600
Officers
| Name | Title |
|---|---|
| Mr. Joshua Riggs | President, CEO & Director |
| Mr. James Liu | Senior Director, Controller & Principal Accounting Officer |
| Dr. Ekkehard Schutz M.D., Ph.D. | Chief Science Officer |
| Ms. Andrea Susan James | Chief Financial Officer |
| Mr. Yuh-Min Chiang Ph.D. | Chief Technology Officer |
| Mr. Peter Hong | VP, General Counsel & Secretary |
| Ms. Sandra O'Donald | Senior Vice President of Business Operations |
| Dr. Michael D. West Ph.D. | Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. |
Exchange: LSE
Country: GB : United Kingdom of Great Britain and Northern Ireland
Currency: US Dollar ($)
| GIC Sector: | Industrials |
|---|---|
| GIC Group: | Commercial & Professional Services |
| GIC Industry: | Commercial Services & Supplies |
| GIC Sub-Industry: | Environmental & Facilities Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 259.9117 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 43 |